For this reason, after tumor engraftment, mice received i.v. infusion of 1 × 106 or 0.1 × 106 CAR.CD19-T cells, followed by the i.p. administration of 100 mg/kg of emapalumab or control vehicle on days 0, 3 and 6 (experimental setting in Fig. 5e, control NT-T cell conditions showed in Fig. 5f). Here, CD19 is linked to neoplasm.